Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals (NASDAQ:RXRX). And retail traders should know. We noticed this today when the positions showed up on ...

Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Palantir's stock is up nearly 10 % month-to-date and has gone even higher year-to-date, as bullish sentiment surges ahead of its second quarter earnings. Tempus AI shares, currently at about $64, have ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...